Reasonable Use of Iohexol Reasonable Use of Iohexol Adverse Reactions

2025/04/10

Related News

Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the Quotscience and Technology Innovation Chinaquot New Drug Achievement
November 30, 2021Recently, Beilu Pharmaceutical Jiuwei Zhenxin Granules were successfully selected into the "Science and Innovation China" New Drug Achievement Case Library of the China Association for Scien...view
Adverse Drug Reaction (ADR) and Treatment of Major Iodinated Contrast Agents
May 13, 2021With the increasing application of iodinated contrast agents, the adverse reactions and risks caused by iodinated contrast agents have attracted much attention.view
Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 21 Industry Guidelines Consensus Teaching Materials
January 23, 2024Recently, Beilu Pharmaceutical's independently developed exclusive pure Chinese medicine formulation, Jiuwei Zhenxin granules, has been included in the "Double Heart Outpatient Construction S...view
Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement
June 24, 2021Beilu Pharma participated in the fifth round of national centralized drug procurement organized by the National Organization for Centralized Drug Procurement and Use of the Joint Procurement Office.view
Congratulations: Beilu Pharma's Iohexol Injection Passed the Consistency Evaluation for Generic Drugs
April 21, 2021Recently, Beijing Beilu Pharmaceutical Co., Ltd received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration (NMPA).view
Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets
July 7, 2023Recently, Beilu Pharmaceutical received the Drug Registration Certificate for two sizes (0.375mg and 0.75mg) of Pramipexole Dihydrochloride Sustained-release Tablets (Pramipexole) from the National Me...view

Reasonable Use of Iohexol Reasonable Use of Iohexol Adverse Reactions

Beilu Pharmaceutical Jiuwei Zhenxin granule was selected into the Quotscience and Technology Innovation Chinaquot New Drug Achievement

Adverse Drug Reaction (ADR) and Treatment of Major Iodinated Contrast Agents

Good News: Beilu Pharmaceutical's Jiu Wei Zhenxin Granules Included in 21 Industry Guidelines Consensus Teaching Materials

Beilu Pharma's Iohexol Injection Won the Bid in the Fifth round of National Centralized Drug Procurement

Congratulations: Beilu Pharma's Iohexol Injection Passed the Consistency Evaluation for Generic Drugs

Beilu Pharmaceutical Obtains Drug Registration Certificate for Pramoxine Hydrochloride Sustained Release Tablets